Emerging role of CD20 blockade in allogeneic hematopoietic cell transplantation - PubMed (original) (raw)
Review
. 2010 Oct;16(10):1347-54.
doi: 10.1016/j.bbmt.2010.01.005. Epub 2010 Jan 18.
Affiliations
- PMID: 20083213
- DOI: 10.1016/j.bbmt.2010.01.005
Free article
Review
Emerging role of CD20 blockade in allogeneic hematopoietic cell transplantation
Mohamed A Kharfan-Dabaja et al. Biol Blood Marrow Transplant. 2010 Oct.
Free article
Abstract
There is growing evidence incriminating B lymphocytes in the pathogenesis of graft-versus-host disease (GVHD). Better understanding of the role of B lymphocytes has uncovered new therapeutic approaches, such as CD20 blockade, which appear to be improving outcomes in allogeneic hematopoietic cell transplant recipients. Administration of the chimeric murine/human anti-CD20 monoclonal antibody, rituximab, prior to hematopoietic cell allografting or as part of preparative regimens appears to reduce treatment-related mortality and to improve posttransplant outcomes mainly by decreasing the incidence and severity of acute GVHD. This beneficial effect of rituximab has not had an impact, to the same extent on the incidence of chronic GVHD, which remains a significant cause of morbidity and mortality following hematopoietic cell allografting. Alternatively, rituximab has been shown to be effective for treatment of cGVHD, but data is limited because of the lack of randomized controlled clinical trials and the small sample size in most of the published series. Incorporation of rituximab into the therapeutic armamentarium of Epstein-Barr virus-associated posttransplant lymphoproliferative disorder has clearly improved the overall prognosis of this dreadful disease. This review highlights the evolving role of CD20 blockade in allogeneic hematopoietic cell transplantation and the need to continue to refine B cell depletion strategies in this setting.
Copyright © 2010 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.
Similar articles
- Clinical utility of rituximab in chronic graft-versus-host disease.
Bates JS, Engemann AM, Hammond JM. Bates JS, et al. Ann Pharmacother. 2009 Feb;43(2):316-21. doi: 10.1345/aph.1L386. Epub 2009 Feb 3. Ann Pharmacother. 2009. PMID: 19193571 Review. - Clinical applications of rituximab in allogeneic stem cell transplantation: anti-tumor and immunomodulatory effects.
Ratanatharathorn V, Pavletic S, Uberti JP. Ratanatharathorn V, et al. Cancer Treat Rev. 2009 Dec;35(8):653-61. doi: 10.1016/j.ctrv.2009.07.004. Epub 2009 Aug 13. Cancer Treat Rev. 2009. PMID: 19682801 Review. - [The role of rituximab in the treatment of ANCA-associated systemic vasculitis].
Roccatello D, Vangelista A, Pani A. Roccatello D, et al. G Ital Nefrol. 2011 Sep-Oct;28(5):474-88. G Ital Nefrol. 2011. PMID: 22028261 Review. Italian. - Prior rituximab administration is associated with reduced rate of acute GVHD after in vivo T-cell depleted transplantation in lymphoma patients.
Crocchiolo R, Castagna L, El-Cheikh J, Helvig A, Fürst S, Faucher C, Vazquez A, Granata A, Coso D, Bouabdallah R, Blaise D. Crocchiolo R, et al. Exp Hematol. 2011 Sep;39(9):892-6. doi: 10.1016/j.exphem.2011.06.006. Epub 2011 Jun 16. Exp Hematol. 2011. PMID: 21703987 - Rituximab treatment before reduced-intensity conditioning transplantation associates with a decreased incidence of extensive chronic GVHD.
van Dorp S, Pietersma F, Wölfl M, Verdonck LF, Petersen EJ, Lokhorst HM, Martens E, Theobald M, van Baarle D, Meijer E, Kuball J. van Dorp S, et al. Biol Blood Marrow Transplant. 2009 Jun;15(6):671-8. doi: 10.1016/j.bbmt.2009.02.005. Epub 2009 Apr 16. Biol Blood Marrow Transplant. 2009. PMID: 19450751
Cited by
- Applying Rituximab During the Conditioning Regimen Prevents Epstein-Barr Virus Infection Following Allogeneic Hematopoietic Stem Cell Transplant in a Children's Cohort: A Retrospective Case-Control Study.
Ruan Y, Chen L, Luo T, Xie D, Cao W, Liu X, Liu Q, Xiao Y, Wu C, Wen J, Li J, Meng J, Wu X, Feng X. Ruan Y, et al. Infect Dis Ther. 2023 Aug;12(8):2071-2086. doi: 10.1007/s40121-023-00841-x. Epub 2023 Jul 20. Infect Dis Ther. 2023. PMID: 37470925 Free PMC article. - Immunological considerations and challenges for regenerative cellular therapies.
Petrus-Reurer S, Romano M, Howlett S, Jones JL, Lombardi G, Saeb-Parsy K. Petrus-Reurer S, et al. Commun Biol. 2021 Jun 25;4(1):798. doi: 10.1038/s42003-021-02237-4. Commun Biol. 2021. PMID: 34172826 Free PMC article. Review. - Virotherapy as Potential Adjunct Therapy for Graft-Vs-Host Disease.
Villa NY, McFadden G. Villa NY, et al. Curr Pathobiol Rep. 2018;6(4):247-263. doi: 10.1007/s40139-018-0186-6. Epub 2018 Nov 19. Curr Pathobiol Rep. 2018. PMID: 30595970 Free PMC article. Review. - Phase II study of CD4+-guided pentostatin lymphodepletion and pharmacokinetically targeted busulfan as conditioning for hematopoietic cell allografting.
Kharfan-Dabaja MA, Anasetti C, Fernandez HF, Perkins J, Ochoa-Bayona JL, Pidala J, Perez LE, Ayala E, Field T, Alsina M, Nishihori T, Locke F, Pinilla-Ibarz J, Tomblyn M. Kharfan-Dabaja MA, et al. Biol Blood Marrow Transplant. 2013 Jul;19(7):1087-93. doi: 10.1016/j.bbmt.2013.04.020. Epub 2013 Apr 28. Biol Blood Marrow Transplant. 2013. PMID: 23632090 Free PMC article. Clinical Trial. - H-Y antigen-binding B cells develop in male recipients of female hematopoietic cells and associate with chronic graft vs. host disease.
Sahaf B, Yang Y, Arai S, Herzenberg LA, Herzenberg LA, Miklos DB. Sahaf B, et al. Proc Natl Acad Sci U S A. 2013 Feb 19;110(8):3005-10. doi: 10.1073/pnas.1222900110. Epub 2013 Feb 4. Proc Natl Acad Sci U S A. 2013. PMID: 23382226 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources